publication date: Apr. 26, 2019
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.
Three faculty members at MD Anderson Cancer Center were sanctioned for failure to ensure confidentiality of review of NIH grants. The scientists also failed to disclose outside funding, academic appointments, and roles in laboratories outside the U.S.
As MD Anderson investigates reports of wrongdoing by its faculty members, it does so with full understanding that the stakes are as high as it gets: the integrity of the NIH peer review system, MD Anderson’s good name, and the future of cancer research.
MD Anderson is the first institution to address the interrelated problems of theft of intellectual property, violation of ethics of NIH peer review, and researchers’ failure to disclose foreign affiliations and sources of funding.
Stealing data obtained through the NIH peer review process is the most egregious of the cluster of rogue behaviors revealed through ongoing investigations of diversion of intellectual property, NIH Director Francis Collins said in testimony before the Senate Appropriations Committee April 11.
The Texas House of Representatives approved two measures that would give the Cancer Prevention and Research Institute of Texas an additional $3 billion to continue operations, and allow the institute to continue funding grants beyond fiscal year 2023.
- $15.1M awarded to Rutgers Cancer Institute of New Jersey for redesignation as Comprehensive Cancer Center
- Inova dedicates Inova Schar Cancer Institute; John Deeken named president
- Letter urges exempting FDA rules from review by Congress and the president
- UPMC Hillman Cancer Center joins Beat AML Master Clinical Trial
- Inivata shows positive clinical validation results and real-world utility for its InVisionFirst-Lung liquid biopsy test
- Trial suggests that treatment de-escalation in HER2-positive breast cancer needs to be personalized
- Genetic testing in women diagnosed with breast cancer decreases cost of care nationwide
- FDA approves pembrolizumab plus axitinib for advanced RCC